Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660543 · ClinicalTrials.gov registry record · NA
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
A NA study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT00660543 is a NA study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 14 participants.
The verdict
NCT00660543, a NA study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with ferumoxytol works as a contrasting agent in assessing early response in patients with glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very small form of iron particles that are injected into the body and taken up by certain tissues which may make these tissues easier to see during imaging. Diagnostic procedures, such as an MRI study with ferumoxytol, may help measure a patient's response to earlier treatment.
Interventions
- DRUG Gadolinium
- DRUG Ferumoxytol Non-Stoichiometric Magnetite
- OTHER Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Diffusion Weighted Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-12 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660543
The ClinicalTrials.gov registry entry for NCT00660543 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gadolinium is the first listed.
NCT00660543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660543 about?
NCT00660543 is a clinical study titled "MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy". This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with ferumoxytol works as a contrasting agent in assessing early response in patients with glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very small form of iron particles that are ...
What is the current status of trial NCT00660543?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2006-12. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00660543?
The interventions under investigation include: Gadolinium (DRUG), Ferumoxytol Non-Stoichiometric Magnetite (DRUG), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (OTHER), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (OTHER), Diffusion Weighted Imaging (OTHER).
Who is sponsoring clinical trial NCT00660543?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.